US health officials are terminating a contract with Moderna Inc. worth up to $766 million to develop vaccines for bird flu, a major setback for the company as it faces additional government scrutiny over immunizations.
Moderna said in a statement Wednesday that the vaccine was shown to be safe and well-tolerated in early clinical studies. It had planned to move the vaccine into later-stage trials with funding from the Department of Health and Human Services, but was notified that the agency is canceling its award.
“Today Moderna received notice that HHS will terminate the award for the ...